Literature DB >> 10022881

The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells.

F Bost1, R McKay, M Bost, O Potapova, N M Dean, D Mercola.   

Abstract

We have previously found that epidermal growth factor (EGF) mediates growth through the Jun N-terminal kinase/stress-activated kinase (JNK/SAPK) pathway in A549 human lung carcinoma cells. As observed here, EGF treatment also greatly enhances the tumorigenicity of A549 cells, suggesting an important role for JNK in cancer cell growth (F. Bost, R. McKay, N. Dean, and D. Mercola, J. Biol. Chem. 272:33422-33429, 1997). Several isoforms families of JNK, JNK1, JNK2, and JNK3, have been isolated; they arise from alternative splicing of three different genes and have distinct substrate binding properties. Here we have used specific phosphorothioate oligonucleotides targeted against the two major isoforms, JNK1 and JNK2, to discriminate their roles in EGF-induced transformation. Multiple antisense sequences have been screened, and two high-affinity and specific candidates have been identified. Antisense JNK1 eliminated steady-state mRNA and JNK1 protein expression with a 50% effective concentration (EC50) of <0.1 microM but did not alter JNK2 mRNA or protein levels. Conversely, antisense JNK2 specifically eliminated JNK2 steady-state mRNA and protein expression with an EC50 of 0.1 microM. Antisense JNK1 and antisense JNK2 inhibited by 40 and 70%, respectively, EGF-induced total JNK activity, whereas sense and scrambled-sequence control oligonucleotides had no effect. The elimination of mRNA, protein, and JNK activities lasted 48 and 72 h following a single Lipofectin treatment with antisense JNK1 and JNK2, respectively, indicating sufficient duration for examining the impact of specific elimination on the phenotype. Direct proliferation assays demonstrated that antisense JNK2 inhibited EGF-induced doubling of growth as well as the combination of active antisense oligonucleotides did. EGF treatment also induced colony formation in soft agar. This effect was completely inhibited by antisense JNK2 and combined-antisense treatment but not altered by antisense JNK1 alone. These results show that EGF doubles the proliferation (growth in soft agar as well as tumorigenicity in athymic mice) of A549 lung carcinoma cells and that the JNK2 isoform but not JNK1 is utilized for mediating the effects of EGF. This study represents the first demonstration of a cellular phenotype regulated by a JNK isoform family, JNK2.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10022881      PMCID: PMC83987          DOI: 10.1128/MCB.19.3.1938

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  97 in total

1.  Oncoprotein-mediated signalling cascade stimulates c-Jun activity by phosphorylation of serines 63 and 73.

Authors:  T Smeal; B Binetruy; D Mercola; A Grover-Bardwick; G Heidecker; U R Rapp; M Karin
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

Review 2.  Therapeutic applications of oligonucleotides.

Authors:  S T Crooke
Journal:  Annu Rev Pharmacol Toxicol       Date:  1992       Impact factor: 13.820

Review 3.  The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation.

Authors:  P Angel; M Karin
Journal:  Biochim Biophys Acta       Date:  1991-12-10

Review 4.  Antisense agents in cancer research and therapeutics.

Authors:  B J Dolnick
Journal:  Cancer Invest       Date:  1991       Impact factor: 2.176

5.  Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails.

Authors:  A J Ekstrand; N Sugawa; C D James; V P Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

6.  Epidermal growth factor receptors and EGF-responsiveness of the human breast-carcinoma cell line PMC42.

Authors:  P Monaghan; M G Ormerod; M J O'Hare
Journal:  Int J Cancer       Date:  1990-11-15       Impact factor: 7.396

7.  Structural alterations of the epidermal growth factor receptor gene in human gliomas.

Authors:  A J Wong; J M Ruppert; S H Bigner; C H Grzeschik; P A Humphrey; D S Bigner; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

8.  Activation of the autocrine transforming growth factor alpha pathway in human squamous carcinoma cells.

Authors:  M Reiss; E B Stash; V F Vellucci; Z L Zhou
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

9.  Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73.

Authors:  T Smeal; B Binetruy; D A Mercola; M Birrer; M Karin
Journal:  Nature       Date:  1991-12-12       Impact factor: 49.962

10.  Growth control by epidermal growth factor and transforming growth factor-alpha in human lung squamous carcinoma cells.

Authors:  G J Rabiasz; S P Langdon; J M Bartlett; A J Crew; E P Miller; W N Scott; J F Smyth; W R Miller
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

View more
  30 in total

1.  Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes.

Authors:  Patrick T Walsh; Loraine M Smith; Rosemary O'Connor
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  Molecular mechanisms underlying the time-dependent autophagy and apoptosis induced by nutrient depletion in multiple myeloma: a pilot study.

Authors:  Yuan Liu; Yan Chen; Lu Wen; Guohui Cui
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

3.  Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation.

Authors:  Cristina Cellurale; Guadalupe Sabio; Norman J Kennedy; Madhumita Das; Marissa Barlow; Peter Sandy; Tyler Jacks; Roger J Davis
Journal:  Mol Cell Biol       Date:  2011-01-31       Impact factor: 4.272

4.  Effects of MAP kinase inhibitors on epidermal growth factor-induced neoplastic transformation of human keratinocytes.

Authors:  Hideya Mizuno; Yong-Yeon Cho; Wei-Ya Ma; Ann M Bode; Zigang Dong
Journal:  Mol Carcinog       Date:  2006-01       Impact factor: 4.784

5.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.

Authors:  B L Bennett; D T Sasaki; B W Murray; E C O'Leary; S T Sakata; W Xu; J C Leisten; A Motiwala; S Pierce; Y Satoh; S S Bhagwat; A M Manning; D W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

Review 6.  JNK signalling in cancer: in need of new, smarter therapeutic targets.

Authors:  Concetta Bubici; Salvatore Papa
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

7.  c-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight junction disruption in the intestinal epithelium.

Authors:  G Samak; T Suzuki; A Bhargava; R K Rao
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-07-01       Impact factor: 4.052

8.  Suppression of Ras-stimulated transformation by the JNK signal transduction pathway.

Authors:  Norman J Kennedy; Hayla K Sluss; Stephen N Jones; Dafna Bar-Sagi; Richard A Flavell; Roger J Davis
Journal:  Genes Dev       Date:  2003-03-01       Impact factor: 11.361

9.  Oral administration of blueberry inhibits angiogenic tumor growth and enhances survival of mice with endothelial cell neoplasm.

Authors:  Gayle Gordillo; Huiqing Fang; Savita Khanna; Justin Harper; Gary Phillips; Chandan K Sen
Journal:  Antioxid Redox Signal       Date:  2009-01       Impact factor: 8.401

10.  Role of JNK in a Trp53-dependent mouse model of breast cancer.

Authors:  Cristina Cellurale; Claire R Weston; Judith Reilly; David S Garlick; D Joseph Jerry; Hayla K Sluss; Roger J Davis
Journal:  PLoS One       Date:  2010-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.